Bank of America Merrill Lynch is pointing the finger at exchange-traded funds for the big selloff in biotech stocks.

"The recent sell-off in high growth industries has been ETF driven, as mutual funds have been net buyers over the last several weeks," said Savita Subramanian, head of US equity and quantitative strategy at Bank of America Merrill Lynch.